Maccura Biotechnology Co.Ltd (300463.SZ)
CNY 11.37
(-0.26%)
CNY 11.37
(-0.26%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 8.11 Billion CNY | -0.52% |
| 2022 | 8.16 Billion CNY | 24.29% |
| 2021 | 6.56 Billion CNY | 3.17% |
| 2020 | 6.36 Billion CNY | 15.79% |
| 2019 | 5.49 Billion CNY | 20.64% |
| 2018 | 4.55 Billion CNY | 27.16% |
| 2017 | 3.58 Billion CNY | 32.79% |
| 2016 | 2.69 Billion CNY | 13.75% |
| 2015 | 2.37 Billion CNY | 95.03% |
| 2014 | 1.21 Billion CNY | 45.32% |
| 2013 | 837.01 Million CNY | 32.96% |
| 2012 | 629.51 Million CNY | 24.62% |
| 2011 | 505.15 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 8.12 Billion CNY | 0.06% |
| 2024 Q3 | 8.2 Billion CNY | -1.17% |
| 2024 Q2 | 8.3 Billion CNY | 2.2% |
| 2023 Q4 | 8.11 Billion CNY | -1.38% |
| 2023 Q3 | 8.23 Billion CNY | -0.03% |
| 2023 Q1 | 8.27 Billion CNY | 1.33% |
| 2023 FY | 8.11 Billion CNY | -0.52% |
| 2023 Q2 | 8.23 Billion CNY | -0.43% |
| 2022 Q4 | 8.16 Billion CNY | -0.12% |
| 2022 Q3 | 8.17 Billion CNY | 1.49% |
| 2022 Q2 | 8.05 Billion CNY | 0.62% |
| 2022 FY | 8.16 Billion CNY | 24.29% |
| 2022 Q1 | 8 Billion CNY | 21.86% |
| 2021 FY | 6.56 Billion CNY | 3.17% |
| 2021 Q4 | 6.56 Billion CNY | -1.02% |
| 2021 Q1 | 6.63 Billion CNY | 4.17% |
| 2021 Q2 | 6.56 Billion CNY | -0.94% |
| 2021 Q3 | 6.63 Billion CNY | 1.01% |
| 2020 Q4 | 6.36 Billion CNY | 2.56% |
| 2020 FY | 6.36 Billion CNY | 15.79% |
| 2020 Q2 | 5.97 Billion CNY | 6.78% |
| 2020 Q1 | 5.6 Billion CNY | 1.88% |
| 2020 Q3 | 6.2 Billion CNY | 3.78% |
| 2019 Q4 | 5.49 Billion CNY | 4.88% |
| 2019 Q3 | 5.24 Billion CNY | 4.03% |
| 2019 Q2 | 5.03 Billion CNY | 6.17% |
| 2019 Q1 | 4.74 Billion CNY | 4.14% |
| 2019 FY | 5.49 Billion CNY | 20.64% |
| 2018 FY | 4.55 Billion CNY | 27.16% |
| 2018 Q2 | 4.01 Billion CNY | 7.42% |
| 2018 Q1 | 3.73 Billion CNY | 4.28% |
| 2018 Q4 | 4.55 Billion CNY | 5.52% |
| 2018 Q3 | 4.31 Billion CNY | 7.59% |
| 2017 Q1 | 2.75 Billion CNY | 2.28% |
| 2017 FY | 3.58 Billion CNY | 32.79% |
| 2017 Q4 | 3.58 Billion CNY | 6.68% |
| 2017 Q3 | 3.35 Billion CNY | 11.29% |
| 2017 Q2 | 3.01 Billion CNY | 9.35% |
| 2016 FY | 2.69 Billion CNY | 13.75% |
| 2016 Q4 | 2.69 Billion CNY | 1.43% |
| 2016 Q3 | 2.66 Billion CNY | 4.84% |
| 2016 Q2 | 2.53 Billion CNY | 7.04% |
| 2016 Q1 | 2.37 Billion CNY | -0.06% |
| 2015 Q1 | 1.23 Billion CNY | 1.63% |
| 2015 FY | 2.37 Billion CNY | 95.03% |
| 2015 Q4 | 2.37 Billion CNY | 3.04% |
| 2015 Q3 | 2.3 Billion CNY | -2.56% |
| 2015 Q2 | 2.36 Billion CNY | 91.12% |
| 2014 FY | 1.21 Billion CNY | 45.32% |
| 2014 Q4 | 1.21 Billion CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2013 FY | 837.01 Million CNY | 32.96% |
| 2012 FY | 629.51 Million CNY | 24.62% |
| 2011 FY | 505.15 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 17.93 Billion CNY | 54.74% |
| Hangzhou Tigermed Consulting Co., Ltd. | 29.69 Billion CNY | 72.66% |
| Dirui Industrial Co.,Ltd. | 3.32 Billion CNY | -144.499% |
| Beijing Strong Biotechnologies, Inc. | 5.17 Billion CNY | -56.871% |
| Medicalsystem Biotechnology Co., Ltd. | 3.48 Billion CNY | -132.698% |
| Guangzhou Wondfo Biotech Co.,Ltd | 5.77 Billion CNY | -40.673% |
| Guangdong Hybribio Biotech Co.,Ltd. | 5.72 Billion CNY | -41.801% |
| BGI Genomics Co., Ltd. | 13.61 Billion CNY | 40.357% |
| Amoy Diagnostics Co., Ltd. | 1.93 Billion CNY | -319.625% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 2.98 Billion CNY | -171.832% |